The United States in Vitro Diagnostics Market Report is Segmented by Test Type (Clinical Chemistry, Molecular Diagnostics, Hematology, and More), Product (Instruments, Reagents & Kits, and More), Usability (Disposable IVD and Reusable IVD), Application (Infectious Diseases, Diabetes, Oncology, and More), and End User (Diagnostic Laboratories, Hospitals & Clinics, and More). The Market Forecasts are Provided in Terms of Value (USD).

United States Diagnostics Market was valued at USD 35.66 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.12%.

Pages	85
Market Size	2024: USD 35.66 Billion
Forecast Market Size	2030: USD 59.73 Billion
CAGR	2025-2030: 9.12%
Fastest Growing Segment	Infectious Disease Testing
Largest Market	Mid-West Region
Key Players	1. Abbott Laboratories, Inc. 2. Danaher Corporation 3. Thermo Fisher Scientific, Inc. 4. Johnson & Johnson 5. Ortho-Clinical Diagnostics, Inc. 6. Becton, Dickinson, and Company 7. Bio-Rad Laboratories, Inc. 8. Roche Diagnostics Corporation 9. Siemens Medical Solutions USA, Inc. 10. Biomerieux Inc.

The United States diagnostics market size is anticipated to grow at a CAGR of 5.17% during the forecast period of 2025-2034 driven by the rising awareness among people about healthy lifestyle.

The global sales of clinical diagnostics is estimated to be worth USD 86.5 billion in 2025 and anticipated to reach a value of USD 147.2 billion by 2035. Sales are projected to rise at a CAGR of 5.5% over the forecast period between 2025 and 2035. The revenue generated by clinical diagnostics in 2024 was USD 82.6 billion.

Attributes	Key Insights
Historical Size, 2024	USD 82.6 billion
Estimated Size, 2025	USD 86.5 billion
Projected Size, 2035	USD 147.2 billion
CAGR (2025 to 2035)	5.5%

Semi-annual Market Update for the Clinical Diagnostics Industry

Particular	Value CAGR
H1	6.4% (2024 to 2034)
H2	6.1% (2024 to 2034)
H1	5.5% (2025 to 2035)
H2	5.1% (2025 to 2035)

Analysis of Top Countries Using Clinical Diagnostic Tools

Countries	Value CAGR (2025 to 2035)
United States	3.4%
Germany	3.9%
UK	3.7%
France	4.2%
China	5.6%
South Korea	5.1%
India	6.0%

Clinical Diagnostics Industry Analysis by Top Investment Segments

By Product type	Reagents and Kits
Value Share (2025)	63.3%

By Test	Infectious Disease
Value Share (2025)	38.6%

The revenue in the 'In Vitro Diagnostics' segment of the medical technology market in the United States was forecast to continuously increase between 2024 and 2029 by in total *** billion U.S. dollars (+***** percent). According to this forecast, in 2029, the revenue will have increased for the fifth consecutive year to ***** billion U.S. dollars. Find further information regarding revenue in Canada and revenue growth in Canada. The Statista Market Insights cover a broad range of additional markets.

The size of the United States In Vitro Diagnostics (IVD) Market market was valued at USD 40.85 Million in 2023 and is projected to reach USD 59.70 Million by 2032, with an expected CAGR of 5.57% during the forecast period. The United States IVD Market covers tests and devices used in diagnosis of a disease or condition together with infections without invasive procedures that require the use of blood, tissue or any other body fluids outside the human body. Several of these are molecular diagnostics, immunoassays, clinical chemistry, and POC testing. Medical diagnostic laboratory plays an important role of diagnosing various diseases such as infectious diseases, cancer, cardiovascular diseases and genetic disorders through IVD. Further, the U. S. market underlies growth in technology, higher longevity rates, growing incidences of chronic diseases, and the growing need for more tailored treatment. Some of the trends include; next-generation sequencing (NGS), digital diagnostics, AI-assisted diagnostic solutions, and growth in at-Home sample collection solutions. Another factor enhancing the growth of this market is the enhancement of the regulation and the development of innovative biomarkers. Recent developments include: In July 2022, the United States Food and Drug Administration (FDA) cleared The Lumipulse G β-Amyloid Ratio (1-42/1-40) test, manufactured by Fujirebio Inc., the first diagnostic laboratory test to aid in the diagnosis of Alzheimer's disease., In July 2022, Roche announced that the United States Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Elecsys Amyloid Plasma Panel, an innovative new solution to enable Alzheimer's disease to be detected earlier.. Key drivers for this market are: High Burden of Chronic Diseases, Increasing Use of Point-of-care (POC) Diagnostics Spurring the IVD Market; Increasing Government Healthcare Expenditure and Consumer's Healthcare Spending; Advanced Technologies Fueling the IVD Market; Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics. Potential restraints include: Lack of Proper Reimbursement, Stringent Regulatory Framework; Need For High Complexity Testing Centers. Notable trends are: Cancer/Oncology Segment Segment is Expected to Witness Growth Over the Forecast Period.

In 2029, the global in vitro diagnostics market is forecast to have revenue of over ***** billion U.S. dollars. Between 2020 and 2021, the IVD market size increased significantly, going from around ** billion U.S. dollars to just under 100 billion U.S. dollars. Market leaders and regional distribution Swiss-based pharmaceutical company Roche has maintained its position as the global leader in the IVD market, with projected revenues exceeding ** billion U.S. dollars by 2024. Other major players include Abbott Laboratories and Danaher from the United States. In Europe, Germany dominates the IVD market with a ** percent share, more than double that of France, the next largest market at **** percent. Market composition The IVD market comprises various product categories, including reagents, instruments, and software services. Consumable products accounted for the largest share of the IVD market globally, representing around ** percent of the total market.

The United States molecular diagnostics market size reached USD 4.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.4 Billion by 2033, exhibiting a growth rate (CAGR) of 4.9% during 2025-2033. The increasing prevalence of chronic diseases, adoption of personalized medication, rapid advancements in technology, favorable government policies, sudden shift towards eco-friendly processes, and the growing collaborations represent some of the key factors driving the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 4.8 Billion
Market Forecast in 2033	USD 7.4 Billion
Market Growth Rate (2025-2033)	4.9%

IMARC Group provides an analysis of the key trends in each segment of the United States molecular diagnostics market report, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on product, technology, application and end user.

Current projections of molecular diagnostic market indicate an estimation of US$ 60,347.40 million by 2034, climbing up from US$ 39,611.00 million in 2024. After an exhaustive assessment of the market, a moderate CAGR of 4.30% is envisaged through 2034.

Attributes	Details
Molecular Diagnostics Market Value for 2024	US$ 39,611.00 million
Forecast Market Value for 2034	US$ 60,347.40 million
CAGR from 2024 to 2034	4.30%

Molecular Diagnostics as a Stimulus for Early Cancer Diagnosis

Attributes	Details
Market Value for 2019	US$ 29,335.60 million
Market Value for 2023	US$ 38,720.40 million
CAGR from 2019 to 2023	5.40%

Category-wise Outlook

Top Product	Reagents and Kits
Market Share (2024)	64.40%

Top Technology	Polymerase Chain Reaction (PCR)
Market Share (2024)	38.70%

Country-wise Analysis

Countries	CAGR (2024 to 2034)
India	5.90%
Thailand	4.70%
Malaysia	4.30%
Indonesia	3.90%

Countries	CAGR (2024 to 2034)
United States	2.20%
Canada	3.80%

Countries	CAGR (2024 to 2034)
France	4.30%
Italy	3.80%
Spain	3.40%
Germany	2.90%
United Kingdom	2.70%

The North American Molecular Diagnostics Market report segments the industry into By Technology (In-Situ Hybridization, Chips and Microarrays, Mass Spectrometry (MS), Sequencing, PCR, Other Technologies), By Application (Infectious Disease, Oncology, Pharmacogenomics, and more), By Product (Instrument, Reagent, Other Products), By End User (Hospitals, Laboratories, Other End Users), and Geography (United States, Canada, Mexico).

Snapshot img

Medical Diagnostics Market Size 2025-2029

The medical diagnostics market size is forecast to increase by USD 79.3 billion, at a CAGR of 6.7% between 2024 and 2029.

The market is driven by the high prevalence of infectious diseases and the global adoption of advanced treatment solutions. The increasing incidence of chronic diseases and the growing need for early and accurate diagnosis are key factors fueling market growth. However, the lack of trained laboratory technicians poses a significant challenge to the industry. This shortage can lead to misdiagnosis, delayed diagnosis, or even incorrect diagnosis, which can have serious consequences for patients. To overcome this obstacle, companies can invest in training programs or partner with academic institutions to attract and develop skilled professionals. Additionally, the integration of automation and artificial intelligence technologies into diagnostic processes can help mitigate the impact of the labor shortage and improve overall efficiency. Companies that effectively address these challenges while leveraging the latest technological advancements are well-positioned to capitalize on the growing demand for accurate and timely diagnostic services.

What will be the Size of the Medical Diagnostics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe market continues to evolve, driven by advancements in technology and the growing demand for early and accurate detection of various health conditions. The application of data analytics and artificial intelligence (AI) in diagnostics is revolutionizing the industry, enabling predictive diagnostics and improving test accuracy. Urine tests, ELISA tests, and PCR testing are being complemented by in-vitro diagnostics, point-of-care testing, and molecular diagnostics. In-vivo diagnostics and imaging technologies, including digital pathology and medical imaging, are providing valuable insights into the human body. Data security remains a critical concern as diagnostic data is increasingly being stored in the cloud. Remote diagnostics and wearable sensors enable disease management from a distance, while turnaround time is being reduced through automation and machine learning. Flow cytometry and clinical chemistry are essential tools in the diagnostics toolbox, providing valuable information on cellular and biochemical processes. The market for diagnostic yield is growing as researchers and healthcare providers seek to optimize diagnostic procedures and improve patient outcomes. Infectious disease diagnostics and preventive diagnostics are key areas of focus, with mass spectrometry and genetic testing playing important roles. The ongoing unfolding of market activities reveals a dynamic industry, with continuous innovation and evolving patterns shaping the future of medical diagnostics. The integration of AI-powered diagnostics, data analytics, and digital technologies is transforming the landscape, offering new opportunities and challenges for stakeholders. The application of these technologies across various sectors, from research institutions to healthcare providers, is driving growth and improving patient care.

How is this Medical Diagnostics Industry segmented?

The medical diagnostics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. TypeIVDDiagnostic imagingOthersEnd-userHospitals and clinicsDiagnostic centersResearch laboratories and institutesOthersGeographyNorth AmericaUSCanadaEuropeFranceGermanyItalyUKAPACChinaJapanSouth KoreaSouth AmericaBrazilRest of World (ROW)

By Type Insights

The ivd segment is estimated to witness significant growth during the forecast period.The In Vitro Diagnostics (IVD) segment is experiencing notable growth in the diagnostics market, surpassing diagnostic imaging and other segments. This expansion is primarily fueled by the increasing significance of molecular, clinical, and immunoassay diagnostic techniques. IVD solutions enable clinicians, researchers, and scientists to identify cellular components for disease diagnosis, providing valuable insights into cell biology. For example, tumor markers, identified through immunohistochemistry (IHC) technology, aid physicians in diagnosing malignancies and determining tumor type, origin, and stage. The demand for IVD tools is escalating due to the growing requirement for advanced real-time diagnostic solutions to facilitate early detection of communicable and chronic diseases. Additionally, cloud computing, machine learning, and artificial intelligence are transforming the diagnostics landscape by improving test accuracy and turnaround time. Predictive

The United States diagnostic labs market is anticipated to grow at a CAGR of 6.50% during the forecast period of 2025-2034, driven by the increased aging population and advancements in molecular diagnostics such as AI, and next-generation sequencing technologies in the region. The market growth is fueled by rising demand for personalized medicine, point-of-care testing, digital health integration, and expanding access to molecular diagnostics.

The market was valued at USD 90,400 million in 2025 and is anticipated to reach USD 146,500 million by 2035, expanding at a compound annual growth rate (CAGR) of 4.8% over the forecast period.

Metric	Value
Market Size (2025E)	USD 90,400 million
Market Value (2035F)	USD 146,500 million
CAGR (2025 to 2035)	4.8%

Country-wise Outlook

Country	CAGR (2025 to 2035)
United States	4.5%

Country	CAGR (2025 to 2035)
United Kingdom	4.2%

Region	CAGR (2025 to 2035)
European Union	4.3%

Country	CAGR (2025 to 2035)
Japan	4.4%

Country	CAGR (2025 to 2035)
South Korea	4.6%

Competitive Outlook

Company Name	Estimated Market Share (%)
Roche Diagnostics	20-24%
Abbott Laboratories	15-19%
Siemens Healthineers	12-16%
Danaher Corporation	10-14%
Other Companies (Combined)	30-40%

The United States cancer diagnostics market size was valued at USD 53 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 108.2 Billion by 2033, exhibiting a CAGR of 8.3% from 2025-2033. The market is driven by the increasing development of personalized therapies that are more effective and less toxic, along with rising demand for detection of genetic mutations associated with cancer.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 53 Billion
Market Forecast in 2033	USD 108.2 Billion
Market Growth Rate (2025-2033)	8.3%

IMARC Group provides an analysis of the key trends in each segment of the United States cancer diagnostics market, along with forecasts at the country and regional levels from 2025-2033. The market has been categorized based on product, technology, application, and end user.

The United States in vitro diagnostics market was valued at USD 19.84 Billion in 2024, driven by the increasing adoption of advanced molecular diagnostics and the growing prevalence of chronic diseases across the region. The market is anticipated to grow at a CAGR of 6.30% during the forecast period of 2025-2034, with the values likely to reach USD 36.55 Billion by 2034. The market is growing due to a robust healthcare infrastructure and continuous technological innovation. Additionally, growing demand for rapid, accurate testing fuels market expansion during the forecast period.

Personalized medicine is reshaping the costs and services of diagnostic and medical labs, necessitating new strategies for growth and competitiveness. There is a rising demand for labs capable of advanced genetic testing, requiring cutting-edge technology and specialized expertise in genetic data analysis. Although these tests have high upfront costs, they can potentially lower long-term healthcare expenses and boost the overall value of laboratory services. As demand grows, labs must effectively manage operating expenses, leading to a trend of consolidation. Mergers allow more extensive networks to achieve economies of scale, invest in new technologies and offer comprehensive services for sustained growth. As new technologies like point-of-care testing (POCT) present ongoing competitive challenges, industry revenues have grown at a CAGR of 2.6% to reach $87.5 billion through 2025, experiencing a 3.6% gain in 2025 alone. The fee-for-service model is gradually being replaced by a managed-cost healthcare framework, which emphasizes fixed service rates and preventive care to reduce overall expenses and these regulatory requirements have increased operational costs for labs. Consolidation among essential buyers—physicians, insurers, employers and pharmaceutical companies—has strengthened their bargaining power, enabling them to drive down prices and internalize testing, lessening the need for external labs. To address the challenges, labs must innovate quickly and explore collaborative opportunities to reduce costs. Technology will continue to reshape industry competition and strategy. Labs are adapting by leveraging automation, AI and digital health technologies that are becoming standard. Robotic automation allows labs to handle more tests with fewer errors, providing a competitive edge. AI revolutionizes data interpretation, reducing the need for specialized human labor and cutting costs while improving accuracy and resource optimization. Telehealth alters patient interactions, encouraging remote access to test results and consultations. To remain relevant, labs must integrate seamlessly with telehealth systems, embrace automation and seek associations or mergers to gain economies of scale. Despite the competitive pressures and challenges, the industry is expected to enjoy continued growth, with revenue strengthening at a CAGR of 3.4% to reach $103.6 billion by 2030, with profit stable.

The global Infectious Disease Molecular Diagnostics Market was valued at around US$ 34 billion in 2021. With a projected CAGR of 4.2% for the next ten years, the market is likely to reach a valuation of nearly US$ 53 billion by the end of 2032. Developers are increasingly relying on scientific developments from a variety of fields rather than the traditional methods that required the culture of the pathogens. Molecular diagnostics is one of the fields in infectious Disease identification that is expanding the fastest.

Report Attributes	Details
Infectious Disease Molecular Diagnostics Market Size (2021A)	US$ 34.0 billion
Estimated Market Value (2022E)	US$ 35 billion
Forecasted Market Value (2032F)	US$ 53 billion
Global Market Growth Rate (2022 to 2032)	4.2% CAGR
United States Growth Rate (2022 to 2032)	4.3% CAGR
Key Companies Covered	Abbott Danaher Corporation bioMérieux SA F. Hoffmann-La Roche Ltd Bio-Rad Laboratories, Inc. Agilent Technologies, Inc. Becton, Dickinson, and Company Hologic, Inc. (Gen-Probe) Illumina, Inc. Grifols S.A. Qiagen Siemens Healthineers AG Sysmex Corporation

Snapshot img

POC Molecular Diagnostics Market Size 2024-2028

The POC molecular diagnostics market size is forecast to increase by USD 1.14 billion at a CAGR of 10.03% between 2023 and 2028. The molecular diagnostics market in the United States is experiencing significant growth due to several key drivers. One major factor is the increasing focus on technological advances, with the development of portable RT-PCR machines gaining traction. These devices offer the convenience of on-site testing, making them ideal for surveillance epidemiology and cancer development research. Another factor is the aging population, as the need for early disease detection and monitoring increases. Environmental factors also play a role, as there is a growing awareness of the importance of accurate and timely diagnosis to mitigate the impact of pollution and other environmental hazards on health. The integration of biosensors, smartphones, wearables, and lab-on-a-chip technology is revolutionizing the diagnostic landscape, enabling pre-emptive and personalized medicine. Additionally, strained laboratory budgets and lowering reimbursements are influencing the sales of molecular diagnostics instruments. Overall, these trends demonstrate the importance of molecular diagnostics in improving healthcare outcomes and reducing costs.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The molecular diagnostics market in the US is experiencing significant growth due to the increasing prevalence of chronic diseases, infectious diseases, and genetic disorders. These conditions necessitate early and accurate diagnosis, leading to a heightened demand for advanced diagnostic solutions. Molecular diagnostics, which include RT-PCR machines, genetic sequencing-based, and PCR-based tests, play a crucial role in identifying various health conditions. They are particularly beneficial in primary care settings, where quick and precise diagnosis is essential. The market encompasses a wide range of products, from shelf products and rapid tests to OTC diagnostics and home care solutions.

Moreover, glucose testing and coagulation testing are common applications of molecular diagnostics, while public health surveillance utilizes these technologies for diseases like HIV. The geriatric population is a significant focus area for molecular diagnostics, as they are more susceptible to various health conditions. HUWEL Lifesciences and Lucira Health are notable companies contributing to the market with their innovative solutions. Advancements in technology, such as 3D printing, have led to the development of more efficient and cost-effective molecular diagnostic tools. These advancements have expanded the market's reach, making these diagnostic solutions accessible to a larger population. Molecular diagnostics have become increasingly important in the diagnosis of diseases like Alzheimer's, Parkinson's, and Turner Syndrome.

These conditions require early and accurate diagnosis for effective treatment and management. The market's growth is driven by the need for efficient and accurate diagnostic solutions, the increasing prevalence of chronic diseases, and the expanding application areas. As research and development efforts continue, we can expect further advancements in molecular diagnostics, leading to improved patient outcomes and enhanced public health. In conclusion, the molecular diagnostics market in the US is a dynamic and evolving industry, driven by the need for accurate and efficient diagnostic solutions. The market's growth is fueled by the increasing prevalence of chronic diseases, the expanding application areas, and the ongoing technological advancements.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  PCR
  Microarray and hybridization


Application

  Infectious diseases
  Oncology
  Hematology and endocrinology
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    France


  Asia

    China


  Rest of World (ROW)

By Product Insights

The PCR segment is estimated to witness significant growth during the forecast period. Gene sequencing through Polymerase Chain Reaction (PCR) plays a crucial role in amplifying nucleic acids to generate multiple copies for detecting and identifying infectious and chronic diseases. Traditional lab methods can take 3-10 days, leading companies to focus on Point-of-Care (POC) solutions using advanced technologies. These include microfluidics, nanotechnology, miniaturization, and 3D printing. Microfluidic POC devices miniaturize PCR processes onto a chip, providing test results in hours or even within three days. PCR technology not only identifies infection-causi

The United States In Vitro Diagnostics (IVD) market, valued at $40.85 billion in 2025, is projected to experience robust growth, driven by a compound annual growth rate (CAGR) of 5.57% from 2025 to 2033. This expansion is fueled by several key factors. The increasing prevalence of chronic diseases like diabetes, cancer, and cardiovascular conditions necessitates frequent diagnostic testing, bolstering demand for IVD products. Technological advancements, particularly in molecular diagnostics and point-of-care testing, are improving accuracy, speed, and accessibility of diagnostic procedures, further stimulating market growth. The growing geriatric population, susceptible to multiple health issues, also contributes significantly to the market's expansion. Furthermore, the rising adoption of personalized medicine, emphasizing tailored treatment plans based on individual genetic profiles, enhances the reliance on advanced IVD technologies. Increased government funding for healthcare infrastructure and research & development initiatives are also positively influencing market dynamics. Competition within the market is fierce, with major players like Abbott Laboratories, Roche, and Danaher Corporation constantly innovating and expanding their product portfolios to maintain market share. However, certain challenges hinder market growth. Regulatory hurdles and stringent approval processes for new diagnostic technologies can cause delays in product launches. High costs associated with advanced IVD technologies can limit accessibility, particularly in underserved populations. Moreover, the market is susceptible to fluctuations based on disease prevalence and healthcare spending patterns. Despite these limitations, the overall market outlook remains positive, driven by the aforementioned growth drivers and a sustained focus on improving healthcare outcomes through early and accurate disease detection. The segmentation by test type (clinical chemistry, molecular diagnostics, etc.), product (instruments, reagents), usability (disposable/reusable), application (infectious diseases, cancer, etc.), and end-user (hospitals, laboratories) provides a granular understanding of the market's diverse landscape, revealing potential growth opportunities within specific niches. Recent developments include: In July 2022, the United States Food and Drug Administration (FDA) cleared The Lumipulse G β-Amyloid Ratio (1-42/1-40) test, manufactured by Fujirebio Inc., the first diagnostic laboratory test to aid in the diagnosis of Alzheimer's disease., In July 2022, Roche announced that the United States Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Elecsys Amyloid Plasma Panel, an innovative new solution to enable Alzheimer's disease to be detected earlier.. Key drivers for this market are: High Burden of Chronic Diseases, Increasing Use of Point-of-care (POC) Diagnostics Spurring the IVD Market; Increasing Government Healthcare Expenditure and Consumer's Healthcare Spending; Advanced Technologies Fueling the IVD Market; Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics. Potential restraints include: High Burden of Chronic Diseases, Increasing Use of Point-of-care (POC) Diagnostics Spurring the IVD Market; Increasing Government Healthcare Expenditure and Consumer's Healthcare Spending; Advanced Technologies Fueling the IVD Market; Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics. Notable trends are: Cancer/Oncology Segment Segment is Expected to Witness Growth Over the Forecast Period.

In 2023, German company Siemens Healthineers had the highest revenue worldwide from medical diagnostics, at over 17.6 billion U.S. dollars. This was followed by GE Healthcare, which had revenue from diagnostics of around 16.5 billion U.S. dollars. In vitro diagnostics (IVD) are one of the prominent segments of the diagnostics industry overall. Although also included in the industry are devices that scan or image parts of the body, such as MRIs, CT scans, and ultrasounds. Market share in the IVD markets In 2022, Abbott Laboratories occupied 20 percent of the IVD market in the United States, followed by Danaher with 11 percent market share. Similarly, Roche Diagnostics and Abbott Laboratories had the largest market share in Europe in the given year. IVD industry revenue and market size The outbreak of the COVID-19 pandemic caused a huge demand for tests that could detect the disease. The IVD industry therefore underwent massive growth in 2020 and 2021. In 2024, the global revenue of the in vitro diagnostics industry amounted to nearly 89 billion U.S. dollars, with an expected growth to 103 billion U.S. dollars by 2029.